EWL.XETRA Edwards Lifesciences Corporation

Healthcare Medical Devices XETRA Stock Exchange
90.16 EUR
Close of Nov 6, 2026
63.38 92.92
Market cap
EUR 51.9B
P/E
62.2x
P/B
5.37x
ROE
11.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EWL.XETRA undervalued?

Graham number

The Graham number of Edwards Lifesciences Corporation cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Edwards Lifesciences Corporation fundamental analysis

No fundamental analysis for Edwards Lifesciences Corporation yet.

Edwards Lifesciences Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The…

Full company profile